In the future, we would analyze the levels of lncRNA CHROMR in DLBCL tumors from patients who are not resistant to rituximab after collecting enough specimens to further support the idea that this overexpression of lncRNA is associated with rituximab resistance. This evidence concerns the gene CHROMR and diffuse large B-cell lymphoma.